Oculis Holding AG (OCS) Interest Expenses (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Interest Expenses of -$42141.2 for Q1 2026, down 215.73% year-over-year from $36411.8 in Q1 2025, and up 6.44% quarter-over-quarter from -$45042.1 in Q4 2025.
Analysis
Oculis Holding AG (OCS) Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Interest Expenses history runs 5 years deep, the most recent figure standing at -$42141.2 for Q1 2026.
- In Q1 2026, Interest Expenses fell 215.73% year-over-year to -$42141.2; the TTM figure through Mar 2026 stood at -$467442.0 (down 1065.87% YoY), while the FY2025 annual figure was $1.0 million, up 38.32% from the prior year.
- Interest Expenses for Q1 2026 stood at -$42141.2, up from -$45042.1 in the prior quarter.
- The five-year high for Interest Expenses was $1.9 million in Q3 2022, with the low at -$1.7 million in Q2 2022.
- The 5-year median for Interest Expenses is -$12401.9 (2024), against an average of $175514.1.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 408.83% in 2024, then sank 2964.51% in 2025.
- Oculis Holding AG's Interest Expenses stood at $1.4 million in 2022, then sank by 98.61% to $18907.0 in 2023, then sank by 178.49% to -$14839.8 in 2024, then plunged by 203.52% to -$45042.1 in 2025, then advanced by 6.44% to -$42141.2 in 2026.
- Business Quant data shows OCS's Interest Expenses at -$42141.2 in Q1 2026, -$45042.1 in Q4 2025, and -$601302.7 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | -390,958.88 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -390,958.88 |
| Mar 31, 2026 | -220,921.81 |
| Dec 31, 2025 | -301,531.92 |
| Sep 30, 2025 | -202,517.74 |
| Jun 30, 2025 | -221,043.91 |
| Mar 31, 2025 | -274,725.88 |
| Dec 31, 2024 | -281,955.90 |
| Sep 30, 2024 | -304,710.71 |
| Jun 30, 2024 | -96,204.03 |
| Mar 31, 2024 | -46,972.97 |
| Dec 31, 2023 | -13,528.25 |
| Sep 30, 2023 | -12,453.68 |
| Jun 30, 2023 | -18,906.98 |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.37 Mn |
| Sep 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | -1.73 Mn |